In this webinar we'll be discussing the various RNA detection methods that are available to help scientists study gene expression patterns and elucidate the roles of different genomic elements in cellular function and dysfunction. Many RNA technologies are readily available including Northern blotting, in situ hybridization and RT-PCR. However, each comes with its own advantages and limitations in signal sensitivity, specificity, and stability. And because RNA detection is commonly carried out on lysed cell samples, a significant amount of information can be lost.
We have with us today an expert panel who will share their knowledge and expertise of different RNA detection methodologies including one that utilizes live cells. They will also present data from some of their current research as well as address questions from our live audience.
It is my pleasure to introduce Dr. Martin Stoddart from the AO Research Institute Davos in Switzerland, and Mr. Don Weldon from EMD Millipore in Temecula, California. Thank you for joining us. We're happy you could be here today.
Before we get started, I'd like to share some information for our online viewers. At the top right of your screen, you'll find photos of today's speakers and the view presenter biography link which you can click on to read more details about their background and research. Just below the speaker's bios, you'll find a link to each video that will be shown during the presentations and you can click on these to play a high-resolution version of the video. Underneath the slide viewer is the resources tab where you can find the link to download a PDF version of the slides and additional information about technologies related to today's discussion.
We'll begin today's webinar with a presentation from each of our speakers and end with a Q&A session during which our panelists will address the questions that are submitted by you, our online audience. If you're joining us live now, you can submit your questions at any time by clicking the Ask a Question button below the slide window. Type your question into the box and then click OK. Please be aware that concise and broadly applicable questions are the most likely to be put to the panel, and whenever possible, please direct your question to a specific panelist.
You can also log in to your Facebook, Twitter or LinkedIn account during the webinar to post updates or send tweets about the event. Just click on the relevant icons at the bottom of the screen. For tweets, you can add the hashtag #sciencewebinar. Finally, thank you to EMD Millipore for sponsoring today's webinar.
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It is now my pleasure to introduce today's first speaker, Dr. Martin Stoddart. Dr. Stoddart completed a Bachelor's degree in biology at the University of Aberystwyth prior to earning a Master's of Philosophy in cartilage biology from the AO Research Institute Davos. He then carried out his doctoral research on cancer angiogenesis at the University of Nottingham, and followed this with an appointment in the Laboratory for Experimental Cartilage Research initially as a postdoc and then as a group head.
During that time, he took a sabbatical at the center for Molecular Orthopaedics at Harvard Medical School in the Brigham and Women's Hospital in Boston to learn viral gene transfer techniques. He then returned to AO Research Institute where he became a principal investigator in 2009. Dr. Stoddart's main research focus is using autologous stem cells and gene transfer to repair musculoskeletal tissues using a cell therapy approach.
Welcome and thank you for being here today Dr. Stoddart.
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Dr. Martin Stoddart: Thank you very much Tianna and thank you for the opportunity to present some of the work we've been doing here in Davos. So over the next few slides, what I hope to achieve is I wanted to describe some of the more routine RNA methods that you find commonly used in labs and give some considerations about their use, and then we'll give you some data from some bone tissue engineering, some practical real-time PCR data and how you should interpret that data and what are some of the pitfalls. Eventually, we're going to look at some of these new technologies which gives you the opportunity to look at RNA methods within live cells.
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So one the earliest methods of RNA detection was the Northern blot. Essentially, what you would do, you would lyze your sample, destroy the sample. This first step of destruction is one of the biggest problems with a lot of the methods used today. Once you've then purified and cleaned up your RNA sample, you would run it on a 2D gel electrophoresis system to separate your RNA by size.
This way you can then transfer your RNA sample to a membrane and you can probe that membrane with specific probes. By making these probes sequence-specific and labeling them with a particular detection method such as fluorescence, or previously it was radiation, you can then start to develop that membrane against the film and look for the particular gene of interest and whether it's being expressed or not.
[0:05:07]
One of the big advantages of this kind of method is that you can look for particular size of a molecule, you can look then for splice variants of the same kind of mRNA sequence and it gives you an idea of RNA quality during the preparation steps. Well, due to the fact that it's labor intensive and it requires quite a lot of RNA, it's pretty much been superseded nowadays by more PCR-based technologies.
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So the polymerase chain reaction technology starts again with a lysis step and then the purified RNA goes through an RT step, a reverse transcription step which gives you double-stranded cDNA. This cDNA you can then look for your gene of interest, again looking with specific primers which then will expand the type and the copy number of the gene of interest exponentially over numerous cycles.
What we would tend to do is run this out, the gene product on a gel which you can see in the black box, and then you can see your gene of interest, and again you can assess the size, you can use it to splice variants. In a semiquantitative way, you can also start to look for how much of the gene was there. One big disadvantage to this method is that it's a semi-quantitative method.
If you go to end-point PCR and you have quite a high concentration, like you can see in the ultra-bands in this particular gel they're actually quite intense. The bands are very intense and the problem then becomes --it can saturate the system giving you a wrong quantification method.
Slide 7
So this is then led to a further refinement, where essentially between the two primers when the PCR is being performed, you would add a fluorescence probe or you'd use SYBR Green which intercalates in the double-stranded DNA, and this then gives you a fluorescence signal based on the amount of double-stranded mRNA signal you have within your sample. So over time, every cycle, the new fluorescence measurement is measured.
As you can see from the red line on this graph, essentially once it gets to a certain critical point, you reach the threshold and that's the quantifications that you can use to refer to against housekeeping genes with normalized gene expression, and then you can start to measure exactly how much of an RNA sample you have within a particular sample.
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Now, one of the problems with all of the methods mentioned so far is they're very destructive. And so what this essentially means is when you then look at what you're getting, you're effectively quantifying the average of a well or a piece of tissue. So if you imagine an increasing signal --and this potentially the most important slide of my presentation.
As your signal increases whether that would be a band on a gel or your CT value getting lower, how do you know whether this is a global response as in the left-hand side where all the cells are increasing in their concentration or whether you have mixed population of cells, like on the right where the population in blue gradually decreases in frequency whereas the population in orange increases in frequency.
What you essentially measure is an average which ends up being a population which didn't exist in the first place. And so this needs to always be taken into account when you're looking at your PCR data.
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One other methodology for looking at mRNA is to look for in situ hybridization which, again, comes back to this idea of a labeled probe system where basically you can have a tissue section and you can look specifically within that tissue to try to locate the mRNA sequence of interest. Again, it gives a semi-quantitative, but this time you have a much more and bigger advantage that you can actually see where your gene of interest is being expressed within a tissue section.
This prime binding to a sequence is also used for microarrays detection systems which can detect thousands of genes, but in the interest of time, I won't be going into that today.
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So when you have these kind of methods you're normally looking for a research question, and within our lab we're looking quite often for bone tissue engineering using primary human mesenchymal stem cells, then you might be looking for early osteogenic markers because you want to investigate different materials or different growth factors and you'd look for protein such as alkaline phosphatase or Runx2. Runx2 is a messenger RNA or it's a transcription factor which can be used to identify certain cell types.
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One advantage of this kind of transcription factors when you're looking at stem cell differentiation is they include master genes with transcription factor such as Runx2 to give you an indication that you're going to get an osteoblastic type phenotype, whereas something such as Sox9 gives you an indication you're going to get a chondrocytic type phenotype. Their functioning cells is to bind short sequences and DNA promoters and basically they activate global regulation of many genes and they provide a very early indication of cell fate which could then show up in experimental times.
[0:10:25]
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When you look at the way these kind of genes are expressed in sequence patterns, you'll see that the multipotent stem cell goes through osteoprogenitors to preosteoblasts and to mature osteoblasts, and the sequences underneath like Runx2, osterix, collagen I, ALP, these are the kinds of mRNA messages which people would traditionally look for to try to determine whether the cells are becoming an osteoprogenitor or not.
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What we find when we started doing this with human stem cells is even though Runx2 is a critical factor in the development of bone in vitro and in vivo, the exact type of stimulus is not so relevant for this particular graph. But what became quite clear was essentially whether they were simulated to osteogenesis or not, we did not get a very clear pattern with this particular mRNA method using real-time PCR as to whether osteogenesis was occurring or not.
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And so that's led us towards looking for other targets. We know from the literature that Sox9 which is this chondrogenic transcription factor has an interacting role with Runx2 and it is actually quite dominant. So then we started to look at the ratio of how these two different factors behave, and for the next, where we're heading, this is where we think is something which will become more and more prevalent is the idea that just looking for a specific marker, of a specific phenotype will not be enough because in general it will be there.
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The question then becomes how does it interact with the other factors of importance? So again, with this graph it's not so important, the exact stimulation used, or what you can clearly see that the Runx2 in blue and orange, there's no particular pattern whereas what actually happens in this these particular cells is that Sox9 mRNA is rapidly down regulated. And then when you do a ratio of Runx2 to Sox9 which is the green bar, you quite quickly see that that's very easy to see which are the osteogenic samples and which are nonosteogenic.
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This also varies between patients so it can be used as an early screening methodology. When you take this ratio on day 7 and then look for a functional outcome such as calcium incorporation, what you find is once it reaches a critical threshold we believe to be around 3 in our hands, you then start to see quite a nice correlation between the Sox9 and Runx2 ratio on day 7 to a functional output on day 28.
This can give you a very nice, quick, easy test to try to obtain information about the patient, the donor, the methodology or the particular scaffold of interest that you're working with. Again, this has the disadvantage still, that it's destructive. You can't really do anything with the sample after you've used it.
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What we then found was if you then silence the Sox9 to increase the ratio, you then as were expected, increase calcium incorporation leading to more osteogenesis. So this ratio is a balance and just looking at one factor alone is not enough. If you look at the cells and the way they differentiate, this kind of makes sense because you have this mesenchymal stem cell on the left here which has the potential to go towards chondrogenesis with the Sox9 factors or it has the potential to go to osteogenesis with the Runx2 factor.
Often both are actually present within the cell and is waiting to reach this critical mass which is the schematic of triangle on the Runx2 line here which essentially, once it becomes towards Runx2, it's heading towards osteogenesis, but once it reaches the critical threshold then it's irreversibly going towards that direction. You would not want to be a confused cell.
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But again, coming back to this slide which I presented earlier, we want to know what do individual cells do and how do individual cells behave, whereas all these PCR data with this average, we don't know all the cells differentiating down one pathway or do we have two or more likely because we're using primary human MSCs which are more likely to have a mixed population with variant things going on.
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So with that in mind, we've been starting to work with this small flat technology from Millipore which the next presenter will discuss in more detail, but for the purposes of my presentation, what's important to know is this probe is taken off by live cells, binds mRNA in the cytoplasm and leads to fluorescence signal within live cells within your well.
[0:15:04]
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What this gives you the opportunity to do is you can then label cells based on their mRNA expression profile and then sort them using a FACS, Fluorescence Activated Cell Sorter. I'm using this data here for example, using the Sox9. What you can see is that the cells which are low fluorescent as were expected expressed low amounts of Sox9, and cells which are high fluorescent expressed high amounts of Sox9. This gives you then a cell population which you can then further investigate, you can culture, you can look functionally.
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So when you're doing this type of study, one thing which is important to realize is that because this is based on the probe, the fluorescent bulb probe binding the mRNA message within the cell, there would be a certain amount of background noise. So this could be controlled for using a scramble control because essentially what would happen is you will never get a completely negative signal. As you treat cells with different treatments, what you also need to be reminded is that you need to have an uptake control because as these probes taken up by endocytosis, the cells then, if they're endocytosis it changes so does their fluorescence uptake.
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Now, we've been looking for a down-regulation of a gene. And so what this means is normally what we would do is we would seed our primary cells, add an uptake control to get an idea of how these particular donor behaves, then after stimulating with osteogenic and control medium, we would then wait a few days before we then apply the Sox9 and the scramble Sox9 probe, because this allows then this change in mRNA message to occur, and then we would FACS the day after the uptake, the Sox9 and the scramble control given on day 5.
One thing we found with these probes is they tend to get into the cells even in 3D gels and with the cells which had a bit of matrix buildup, so we can culture the cells for pretty much a week before adding the probe and that works fine in our hands.
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Then when you do this, what you now start to see is you can start to sort the cells with the FACS machine again, and what you'll notice is the gray is basically the control negative just to get an idea where the cells normally would be with no fluorescent marker. The blue here is the scramble, so this is the native background signal which you would always find and the green is the uptake control.
Now the interesting point from our point of view if is if you look at the red Sox9 labeled cells, in the differentiation medium you see a dramatic shift in the peak from being brightly fluorescence to be more dimly fluorescent, and this exactly the same kind of signal we were seeing with the destructive PCR method but now we're doing this on live cells with the ability to sort and keep working with the cells.
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Using this ratio, one thing in this particular sort you can see is we've sorted with Sox9 and Runx2 and this is a single population of cells where you can see a very dramatic difference in the expression of these two genes. As expected, when you sort and then message your RNA by PCR, as a fluorescence intensity of each of the markers goes down, the signal you detect from PCR also goes down.
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But now when you start looking at these different cell populations which would normally be one population where you'd get the dramatic average, you can start to see quite large differences in gene expression profiles as some of the musculoskeletal factors we're interested in. So the blue population which is high Sox9 and high Runx2 also has high ALP or alkaline phosphatase compared to the lower population which are purple and orange in this case, whereas as the fluorescence intensity of these two markers decreases, the expression of collagen I tends to increase. Then the other marker such as osteocalcin which is a late bone marker doesn't really change very much.
And so what we've been doing now while looking at these different factors is were starting to use different gating populations so that we can start looking at a cell which has high Runx2 and low Sox9 versus a low Sox9 and high Runx2 and how do they differ. These kind of studies just can't be done using normal real-time PCR as far as we're aware, and it also gives the opportunity then to start looking at the frequency of the cells, how often does the cells become what you actually wanted it to become in a differentiated state.
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So I now I hope you'll agree that when you're starting to look at these kind of bone tissue engineering approaches, these early osteogenic markers such as alkaline phosphatase and Runx2 should also be supplemented with Sox9 for example, and then look at the ratio of Sox9 to Runx2 to determine is it a genuine up-regulation of Runx2 or is it just kind of a nutritional defect whether the ratio might not change at all.
[0:20:03]
And so basically now, rather than looking for Runx2 alone, the early screening method in our hands is now the Runx2 to Sox9 ratio and we're starting to investigate that more and more at the live cell level using these SmartFlare probes.
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And with that, I'd like to thank the people who've been doing the work, Bojun Li and Claudia Loebel, and also Ursula for all her help with the FACS, and our sponsors who helped in the EU and the probes that we got from Millipore. Thank you very much for your attention.
Tianna Hicklin: Thank you Dr. Stoddart. And just a quick reminder to our live audience, please feel free to submit your questions at any time by clicking the Ask a Question button below the slide viewer.
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Our second speaker today is Mr. Don Weldon. Mr. Weldon holds a Bachelor's degree in cellular and molecular biology from San Diego State University. He also received a certificate in recombinant DNA technology from the same institution. He has worked in the biotech industry as a research scientist for over 11 years with a focus on emerging technologies including gene targeting in mice, molecular analysis of transgenes using GFP variants at the single cell level, and developing flow cytometry reagent kits to speed up assay development time for researchers. His current focus involves working on a novel technology for RNA detection in live cells.
Welcome and thank you for joining us today, Mr. Weldon.
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Mr. Don Weldon: Thank you Tianna. I'm excited to talk to you today about live cell RNA detection technology that's kind of revolutionizing how people are looking at RNA in living cells. I think we can see from Dr. Stoddart today that it's really enabling some experiments that previously were unable to be accomplished.
And so today for my section, I think I'll cover a little of background on the SmartFlare live cell RNA probes, and then I'd like to go into an experiment where we really illustrate the benefit of identifying RNA levels in live cells and what that really allows you to do downstream. Dr. Stoddart gave you a great example of being able to identify RNA within his cells and then used those cells for his downstream functional assays and we'd like to do something similar with a little bit of a twist on it.
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Before we get started, I'd really like to talk a little bit about why we would like to study RNA in a living organism or a live cell. So when studying fixed or live cells, we find that we really lose the context of a living organism and how dynamic it is. We really lose the ability to understand how an organism or a cell within a population adapts and responds to its individual environment.
It's very difficult to do that by taking a snapshot and looking at a fixed or a live cell when we know how dynamic RNA biology really is.
And so with that, I think there's three main areas when studying a live organism we should focus on. Those areas really are to observe with minimal to no disturbance, to identify the individuals of interest and then to leave with minimal to no disturbance. So if you think about this, this acts a lot like how an observer within nature would study a living creature. 
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So to that end, to really observing without doing any disturbance or changes to our cells of interest, and we're talking about RNA now. There's three main areas that we would worry about if we're looking at RNA biology. One of which is the most important is really cell viability. We want to understand that we don't affect the cells' viability at all if we're trying to understand its gene expression.
Number two, do we have some sort of an impact on the gene expression levels within the cells? The last thing you want to do when you're trying to understand the RNA biology within a cell is to alter or change its gene expression just by your detection method. Third and lastly is what does that do to the proteins that are affected by the detection method itself.
And so, here, we have three panels highlighting that there's really no change in cell viability, gene expression or protein expression, or translation with the use of the live cell probe. So SmartFlare won't affect the overall health and status of the cells themselves.
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So this is a general workflow. Those get added to a cell culture media. That media can then be placed over the cells and allowed them to incubate overnight. The following day, as far as the readouts go for this technology, the readout is generally their microscopy or flow, high content works as well and really anything to identify a cellular localization of the fluorescence intensity within that cell.
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So Now, what you'll notice before we start the video is that for the first six hours which is about the first quarter of this video, you're really not going to see anything at all and that's because through that endocytosis process the particles actually enter the cells and while they're in the endosome they're not encountering any of their target, so you're not going to see much fluorescence at all.
Once those endosomes open up after about six hours, the particles then are free to interact with targets inside the cell. The particle finds its target of interest, it will release that flare signal and you'll start to see fluorescence release over time. This is a pretty obvious example and that the SKBr3 is expressed ERBB2 where the MCF7s do not. We're probing here for ERBB2 and we're looking for the presence of that mRNA within the cells. So right about here, we're reaching about six hours. So the endosome is open. You'll just start to see some fluorescence occurring in the panel on the right, and then over time as the particle finds more of its target within the cell, you'll start to get more and more release where the fluorescence values gets much higher than the earlier detection time points. This gives you a flavor for how these experiments occur within the cells themselves and really getting that kind of dynamic detection over time.
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So now I'd like to cover an example that I think really highlights the ability of SmartFlare to look at a live cell. These are immune cells we'll be looking at, and identify a population of interest, and then use those same cells that we've identified for downstream assays which is really the benefit of doing anything with a live cell. If we weren't going to use the cells again, it really doesn't matter whether we destroy them or not. In this case we'd like to use those same cells and understand a little bit more about them, further characterize them, use them in a downstream assay and really understand them more from an RNA standpoint.
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So before we get into that, I'll give you a little bit of background on this experiment. In this case we used a probe for c-Myc. So c-Myc is a transcription factor. It has downstream target genes that really play a role in cellular proliferation. As many of you know most cancers are known to show constitutive c-Myc expression.
And so we pulled a paper and this paper was from Experientia and this paper highlighted THP-1 cells. These are monocytic cell line and they took these THP-1s, they differentiated them to macrophages through standard PMA treatment and then they looked at gene expression levels within those cells. We can see from the table here which is table 2, you can see that some of their genes were increased in expression, some of them were unchanged and some of them decreased their expression. Now, interestingly you'll see that c-Myc is decreased in the transition from a monocyte to a macrophage. And so we took this information and said, "Well, what if we could dynamically monitor this over time? What if we could monitor the c-Myc levels within the cells during the differentiation process?"
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And so I have a quick schematic here to highlight what we did. We started with a group of THP-1 monocytes. These are high-end Myc expression. We added our Myc SmartFlare probe and we see very high levels of fluorescence within those cells. Following that, we differentiated those cells using a PMA treatment, and we watched the levels of the RNA change within some of those cells. After day 1 there was enough of a change in the expression level to actually FAC sort those cells.
[0:30:17]
So based on their fluorescence intensities we sorted them into two groups, those with lower expression and those with higher expression. We then cultured both groups of those cells for four additional days to complete the differentiation process. Just to highlight once again, this whole process is really the same three identifiers as we've entered the cell without disturbing it. We're still able to differentiate those cells. The cells have not changed just based on the detection method.
We were able to identify the cells of interest by pulling them out, by FAC sorting, and then we leave those cells without disturbing the cell. The SmartFlare probe actually exits the cell also over time through exocytosis and the cells are basically unchanged, unharmed. You can use those cells for your downstream assays.
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So once we have those two populations of cells. We decided to do some functional assays. This is the benefit of having a live cell to work with at the end of the day. One of those is we can look at the cytokines that were actually secreted from the individual cells whether they were high in fluorescence or low in fluorescence, or in our case, what we're calling premacrophages and the lows and the undifferentiated THP-1s and the highs. We know that the macrophages and monocytes should definitely have a different cytokine expression profile. And so by syphoning off small portions of the media over time, we could really look at this expression profile of the cells themselves.
Then the second functional assay we did was kind of an interesting one. We took these two cell types both known to be phagocytic but macrophages much more so than the monocytes and we added a fluorescent E. coli bacteria, then we wanted to see will this cells still function as normal and actually phagocytize these bacteria over time. And so we have time lapse movie which is actually quite interesting to watch at the end of this.
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So just to prove to ourselves that we were looking at the same change in RNA expression level, we took our day 0, at the time just prior to PMA treatment and our day 5 which was the end of our experiment, and we wanted to understand what do the RNA levels look like today? By qRT-PCR we can see that at day 0 we have high levels, and at day 5 we have a much reduced level of RNA for the c-Myc by qRT-PCR. Now the panel on the right is actually showing the SmartFlare values for those same samples. In day 0 we have high levels as well and by day 5 we have a much more reduced level of RNA based on the SmartFlare detection in the live cells.
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So now if I can take you through a little bit of this experiment, you can go on this journey with us, you can really look at the RNA expression level over time. So we've taken some microscopy images of those cell cultures starting at day 0 where we have high levels of c-Myc in the monocytes. The monocytes look like traditional monocytes. They're rounded. They have high levels of their Myc expression, so the fluorescence values are quite high, and this is day 1.
So when we start to look a little bit later in the experiment. So this is at day 2, what you can start to notice is that we have a much more reduced fluorescence signal. But we also started to see changes in morphology of those cells. The cells are starting to elongate more. They're beginning to attach to the bottom of the culture and they're becoming much more dendritic in nature and much more like a macrophage would.
And then as we look at day 5, we can clearly see that we've reduced this level of fluorescence to almost undetectable by microscopy and the cells expressed that typical phenotype of a macrophage over time and they are starting to move about the culture at the bottom of the plate and adhere as well.
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So now that we have gone through this process of differentiation, we decided to do some expression profiling of those cell types of interest.
Remember we talked about actually pulling off some of the media and using those samples for understanding their RNA profile. So this first graph I'm showing here actually shows the Myc highs which in our case will be the blue bars. The blue bars here at the monocytes. The red bars would be what we're considering macrophages or Myc low. They decreased their expression of Myc.
We looked at several different cytokine markers through Milliplex assay. This assay allows us to look at the secreted proteins within the media, and we looked and what we can find is without going into much detail about each of these, that the two cell types definitely have a distinct expression profile and this is to be expected. We would expect that our macrophages would be secreting different factors that are our monocytes would and this is illustrated quite nicely in this Milliplex assay.
[0:35:16]
So if we take this one step further, if you'll notice the TNF alpha from that first experiment, they're both quite equal. They're very low. There's really no TNF alpha expression going on within the cell cultures as indicated. If we treat each of those fractions with LPS and when we try to stimulate both of the populations what we find is that the Myc lows or the macrophages respond quite nicely to the TNF while the Myc highs actually do not respond. So instead of just an expression profile, now we're looking at a response profile.
Showing once again based on detection, these cells aren't really changing their expression or how they adapt to their environment, but rather performing the same as they would prior to sorting and detection of their RNA of interest. If we look at actually all of the expression profile, and we did the same LPS stimulation across all of the original samples, and what you can see that the macrophages definitely respond differently than the monocytes do allowing you to really profile within those cell types their expression for each of these individual cytokines.
Slide 43
The last thing I was going to leave you with is this movie. So this really kind of highlights the difference between the two cell types. Now, we mentioned we use SmartFlare for the identification of these THP-1 monocytes and their differentiation to the macrophages. The SmartFlare was actually left in the media throughout the entire experiment. And so what you can see is that while we still see very high levels of the c-Myc, and the panel on the left, those are our monocytes.
In the panel on the right we see a much reduced signal of that c-Myc because these are the sorted cells that we've enriched for originally. We took those two fractions of cells and then we added this fluorescent green bacteria to them to see how they would respond over time and then we took a time lapse microscopy. So what you're going to see in this video is you'll see two panels. But first you'll see this high 30,000-foot view where you can see a lot of the different cells moving around and the bacteria transitioning through and then over time they'll start to zoom in on a given area, those orange boxes where you can really see the individual cells of interest.
I'm going to go ahead and play that movie for you now. So it's interesting, what we'll see is within the monocyte fraction, while some of the cells will take up a few of the bacteria, it's really not their ultimate job. They're the circulating cells. It's the macrophages that move into the tissues and start to engulf these bacteria. You'll see that there's a high level of enrichment within the cells but it macrophages over time.
Again, the high resolution version is on the right which really gives you a much better feel for what's going on. But what we find is that within the monocyte fraction, the bacteria tend to be extracellular and still freely moving throughout the culture, whereas within the macrophage fraction they tend to be aggregated within the cells as they're being phagocytosed over time, and we got a much more sparse areas throughout the extracellular space as they're starting to be eaten up by these cells.
Slide 45
In summary, I think what we wanted to show you is what we kind of highlighted today, that we've detected native RNA in living cells during a differentiation process which is a very dynamic process. We know that there's a lot of interaction and signaling that occurs within a differentiation. There's dynamics within a population. We understand that that population will respond differently to factors that are affecting cells within the differentiation. The cells are signaling each other sending out signals that one cell is differentiating and maybe another one neighboring may not. This is a very dynamic area. As Dr. Stoddart alluded to earlier, looking by qRT-PCR and averaging what we see within a population is not a very good method for understanding the individual contribution of the cell during this process. The protocol that we've identified was simplified and that it's a direct addition to the cell culture. We don't have to go through this extraction process and amplification of targets within that before we start to understand what the content of the cells was.
We've enriched for those cells based on their RNA content which is a totally new thing to do in a live cell. This allows us to look at things other than just surface markers when we're enriching for cells of interest. Lastly, we were able to perform these additional functional assays which are quite dynamic and really allow us to separate out cells based on their RNA expression prior to using those cells in a downstream functional assay.
[0:40:02]
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So as we alluded to earlier, all good experiments utilize the proper controls. It's very important to make sure that when we're understanding the RNA level that we understand how a given technology may work. There are three controls that Dr. Stoddart talked about earlier as well: the uptake control, the scramble control, and our housekeeping genes. All of these extremely important when understanding what happens throughout your experiment and making sure that you know that your RNA expression level changes are relative to the controls and that your data is sound at the end of the day.
For this reason, we've developed a starter kit which includes all three and allows you to kind of go through and use them as normal. You can visit our website and also see more information about live cell RNA detection today.
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Lastly, I'd like to thank the group of scientists who are actually doing a lot of this work, Yuko Williams, Alex Ko and Haizhen Liu here in EMD Millipore. I'd also like to thank EMD Millipore for letting us have fun with science and get to do some of this live cell RNA detection today. That's it.
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Tianna Hicklin: Thank you Mr. Weldon. Now, we're going to move right along to answering some of our audience questions. A quick reminder to our live audience, you still have time to submit your questions. Just click the Ask a Question button below the slide window.
Our first question from our online viewers is which technique is most suitable for cancer cell transcriptome and biomarker analysis, northern in situ hybridization, RT-PCR, microarrays or in vivo analyses? In your opinion are there advantages and disadvantages? Perhaps we could start with you Dr. Stoddart.
Dr. Martin Stoddart: Yeah, I would think with this question, essentially one of the methods which we didn't really discuss in great detail during this presentation, and when you're trying to find out which kind of markers are relevant, you would probably start off with a microarray where you could screen thousands of different genes all in one go, and then once you've got some more targeted molecules, you could then confirm your results using the most specific realtime PCR to ensure that the data you see in a microarray is genuine.
Tianna Hicklin: Mr. Weldon, did you have anything to add?
Mr. Don Weldon: No, I think that that's actually quite a good insight. I think profiling the cells ahead of time to understand which genes of interest we're interested in. Confirmation with quantitative measure through RT-PCT makes a lot of sense. I think the last thing I would say in additional to that, maybe adding in some of the live cell detection to that same workflow and allow you to not only sort and enrich cells based on their expression level, but study them independent of the rest of the population just as we've talked about today.
Tianna Hicklin: Great. Thank you. When you're looking at different types of RNA, does this affect your decision about choosing the technique? Perhaps Mr. Weldon we could start with you?
Mr. Don Weldon: Sure. So I think from the live cell standpoint, we actually do not enter the nucleus. It's an important point. So a lot of the wrong noncoding RNAs or the pre-micro RNAs or any of the preprocessed mRNAs are out of the detection space for us. The traditional techniques would be better at identifying, but within the cytoplasm, any of the mature mRNAs or microRNAs are a fair game. In another approach, the other thing which you could do with this kind of thing is when you give a particular stimuli, is it just how they reacted to a small population themselves or does it more generally affect a larger number of cells? Then you could really start to distinguish which therapies are going to be much more practical for a broader donor population rather than ones which are spectacular but only in a few patients.
[0:45:24]
Tianna Hicklin: This one is for both of you. Can you describe the differences in designing controls for both your PCR experiments as well as the live cells?
Dr. Martin Stoddart: Well, in my experience once thing I've noticed is that when you're dealing with live cells which is something we started with relatively recently, especially when you starting to look into how the cells take the probes up. Some of the treatments change the endocytosis right which means then the scramble control which we discussed earlier, which gives you natural background rights, if the endocytosis right increases then the natural background right will also increase.
So you really need to establish how well the cells take the probes up before and after treatment. If you're using a more standard method such as realtime PCR, then you need to be careful which particular housekeeping gene and which controlled probe you use to reference all your gene regulation to because a lot of these housekeeping genes, although they're not supposed to change with treatments, very many of them do.
So for example, we do loading experiments as well with mechanical strain and that I can actually change the GAPDH expression quite considerably. When you're differentiating cells from one phenotype, which is like the stromal fibroblasts-like cells into either an osteoblast or a chondrocyte for example, there's no guarantee that the housekeeping gene is expressed the same in the MSC as it is in the chondrocyte. So for example, we've been using RPL13A a lot which tends to be quite stable across different phenotypes. Today what we find is typically targets that amplify prior to cycle 34 and standard RT-PCR. We have detected quite well which is pretty impressive given that we don't really amplify the signal. We're doing direct native RNA detection. That seems to be kind of our limitation that targets and amplify after cycle 34. We don't really see much of those targets or at least changes in their levels over time.
And so for us, things that amplify prior to cycle 34 are fine for us, I think. As far as the other detection methods go, obviously, qRT-PCR is quite sensitive and you can get some very good detection down to CT value numbers which can be extrapolated through standard probes to actual concentrations which are in a much lower range than what we could detect in a live cell.
Dr. Martin Stoddart: The only thing I'd like to add to that point, I think Northern blots are obviously the ones which require the largest amounts of material. But the other thing to bear in mind when doing PCR and real-time PCR is the purity of the RNA sample can make a huge difference to the results you get, and quite often the mistake I see within the labs here is that people are trying to get every last molecule of mRNA message which means then they have contaminants, and because these methods are enzymic-based then it interferes with the efficiency of the enzymic reaction.
So sometimes you can actually get much, much better results by having lower quantity of mRNA but of a much higher quality and much better efficiency of the enzyme. So that's just something to bear in mind when doing PCR for sensitivity. Tianna Hicklin: Would you be able to elaborate a bit on the half-life of the probes and more about how they're eliminated from the cells? I think you mentioned exocytosis.
Mr. Don Weldon:
Sure. So what we found is that the probes themselves, so if you add the probe to the culture media the night before, you let them incubate overnight and we read them out the next day. If you remove the cells from the culture media and you culture your cells as normal, replacing the media once a day. What we find is that the fluorescence value is for an average expressed target are gone from detection by microscopy or by flow. By day 3 to day 4, there's really no more detectable signal left in the cells.
What we find my MacSpec is by day 5 or 6, we see that the probe has completely left the cell, and that we can't detect those signals of gold which will be the small particle that would be left in the cell over time. So what happens is over time, the cells start to exocytosis, the particle as well. It's kind of a dynamic state. They take in particle but they also secrete particle. And so, if you don't have particle present in the media and you're starting to remove that media once a day, eventually you basically "wash it out" of the cells through their exocytosis process. If we're talking about a mutation that maybe occurs and causes a friendship, an early termination or something where we're losing an axon or two, then in that sense you certainly could still use some of the more traditional techniques such as RNA FISH, Northern. You could look for the absence of that band to that given region and also live cell as well would still work in that case, when we're really looking at large change within the transcript itself and you can look for a loss of signal over time.
Tianna Hicklin: Are any of these techniques useful for measuring a large number of genes simultaneously from single cells with minimal disturbance to the cells and tissues, specifically around thousands of genes?
Mr. Don Weldon: I'll answer it first. I think Dr. Stoddart would have a better answer for that. I think we kind of covered this a little bit with the profiling. So when we start to profile thousands of genes, the easiest way again is going to be an array and that is quite disturbed. We're going to have to lyze the cells and look at their RNA content for those arrays.
I think in the profiling space, understanding upstream, kind of what happens within a cell. We really need to do the more destructive techniques today so far until the next gen thing comes out that allows us to start to look at very many targets. When we talked about the live cell RNA detection we're looking at two-color today which is certainly not in that profiling type space, but really allows you to look at the more discreet events within a single cell. Mr. Don Weldon: To date we don't have any data on plant cells, so we don't know if customers are starting to use them in plant cells. My guess is that they haven't, that we haven't seen too many custom probes come through. Most of the targets we developed have been so far in human, mouse, and rat just because most of the researchers today are doing live cell work or kind of working in that space.
With the plant cell, it would probably be more around the cell wall and penetration of the probe itself. But, again, none of that work has really been done so we're not quite certain about the feasibility of looking at RNA levels within a live plant cell. Mr. Don Weldon: Yeah, I would agree. I think the other problem is the techniques that are available today before SmartFlare came out was you had to look at either of the protein or the RNA. You had to either lyze your sample and look at the RNA levels or keep a small fraction of that and look at the population-based version of that. As we know looking at heterogeneity and RNA levels as well as the protein levels is that there's quite a variants across the population.
So today being able to look at the RNA level within a live cell, what that allows us to do especially in the intact cells, we're looking at proteins on the surface so you could understand the RNA level on the inside and relative to that you can see expression levels of protein on the outside. So you start with some of those experiments as well within live cells where you're not having to fix or permeabilize the cell and you can understand the dynamics between the two.
But as Dr. Stoddart alluded to, again, there's no direct correlation. Some proteins have a much longer half-life as do some RNAs. So you can see dynamic changes over time but that is the way to actually study both within the same cell.
Tianna Hicklin: Well, unfortunately we are out of time for our webinar. I must conclude our Q&A session. I'd like to thank each of our wonderful panelists once again for being with us and for the great talks and discussion they've provided, Dr. Martin Stoddart from the AO Research Institute Davos.
Dr. Martin Stoddart: Thank you very much.
Tianna Hicklin: And Mr. Don Weldon from EMD Millipore.
Mr. Don Weldon: Thank you very much.
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Tianna Hicklin: Thank you to all of our online viewers for your great questions. I'm sorry we didn't have time to get to them all. For more resources related to today's discussion, please visit the URL now listed at the bottom of the slide. This audio webinar will be available to listen to on demand within the next 48 hours. We encourage you to share your thoughts about the webinar by sending an email to the address now in your slide viewer, webinar@aaas.org.
